Allergies Dermatology Marketing 
pharmaphorum
DECEMBER 29, 2021
The green light comes later than Leo hoped, as the FDA turned down the dermatology specialist’s first attempt last year, despite making it through regulatory reviews in the EU, UK, Canada and UAE where it is already launched as Adtralza. Leo now says it will start rolling the new product out in February. billion in the same year.
The Pharma Data
JULY 11, 2021
3 These data are being presented at the 2021 European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress in Krakow, Poland and Madrid, Spain. Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. percent (-100; 852.8), and the median reduction was 97.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 3, 2021
We have a particular passion for allergy, dermatology and specialized care, and specialized nutrition. Our presence covers operations in R&D, supply and sales & marketing in Italy, UK, Germany, the Netherlands, Spain, Sweden, Norway and the US. 4, 2021 11:00 UTC.
pharmaphorum
DECEMBER 9, 2021
Johnson & Johnson Consumer Health focuses its external innovation efforts on Self Care, which consists of allergy, smoking cessation, pain, digestive health, and cough and cold; and Skin Health, which includes acne, sensitive skin, skin protection and aging skin support. Self care, skin health and technology innovation.
The Pharma Data
FEBRUARY 5, 2021
CoolSculpting ® has been an industry-leader, creating the market for non-invasive fat reduction over 10 years ago. American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. “The number one aesthetic concern for consumers is excess body fat 1.
pharmaphorum
SEPTEMBER 29, 2022
Development in peanut allergy has also been discontinued, said Sanofi in its second-quarter update. The drug is also being tested in some forms of chronic obstructive pulmonary disease (COPD) and various conditions leading to urticaria (hives), although it fell short in a phase 3 trial in chronic spontaneous urticaria (CSU) earlier this year.
The Pharma Data
JANUARY 12, 2021
Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.
Expert insights. Personalized for you.
111 
Let's personalize your content